Additionally, it is important to elucidate the molecular components that determine TRAIL-receptor preferences in order to be able to select the best TRAIL agents to potentially treat pancreatic cancer and other tumour types in the future. The gene discussed is TNFSF10; the disease is familial pancreatic carcinoma.